10-Q: Bullfrog AI Holdings Reports Q1 2025 Results, Cites Going Concern Uncertainty

Bullfrog AI Holdings reports its Q1 2025 financial results, highlighting a net loss and raising concerns about its ability to continue as a going concern.

Summary

• Bullfrog AI Holdings, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is focused on using AI/ML to analyze complex data sets in medicine and healthcare.
• Bullfrog AI has had negative cash flows from operations and a net loss since its inception.
• As of March 31, 2025, the company's cash balance was approximately $3.8 million.
• The company's cash and cash equivalents are not sufficient to fund planned operations for at least a year beyond the filing date.
• This raises substantial doubt about the company's ability to continue as a going concern.
• The company anticipates raising additional capital through various avenues, including sales of equity securities and debt transactions.
• The company did not generate any revenue during the three months ended March 31, 2025.
• The net loss attributable to common stockholders was $2,017,553, or $0.21 per share, compared to a net loss of $1,920,568, or $0.26 per share, for the same period in 2024.
• Research and development expenses increased to $576,260 from $552,126 in the prior year.
• General and administrative expenses increased to $1,480,360 from $1,413,592 in the prior year.
• The company is actively engaged in developing and pursuing new intellectual property.
• Management identified material weaknesses in its internal controls over financial reporting at December 31, 2023, which continue to be unremediated as of March 31, 2025.
• On April 25, 2025, the company entered into an At-The-Market Sales Agreement with BTIG, LLC, to sell up to $20 million of common stock.

Sentiment

Score: 3

Explanation: The document presents a mixed picture, with some positive developments in intellectual property and partnerships, but significant concerns about the company's financial position and internal controls. The going concern warning and lack of revenue weigh heavily on the overall sentiment.

Positives

• The company is actively engaged in developing and pursuing new intellectual property.
• Bullfrog AI entered into a collaboration agreement with Eleison Pharmaceuticals Inc. in February 2025.
• The company is implementing improvements to its internal controls over financial reporting.

Negatives

• Bullfrog AI has had negative cash flows from operations and a net loss since its inception.
• The company's cash and cash equivalents are not sufficient to fund planned operations for at least a year beyond the filing date, raising going concern doubts.
• The company did not generate any revenue during the three months ended March 31, 2025.
• Management identified material weaknesses in its internal controls over financial reporting at December 31, 2023, which continue to be unremediated as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is dependent on obtaining necessary financing or revenues.
• There is no assurance that additional funding sources will be available or on terms acceptable to the company.
• Failure to raise sufficient funds may force the company to delay, scale back, or eliminate research and product development programs.
• The company currently does not have commitments for future funding from any source.
• Material weaknesses in internal controls over financial reporting could lead to material misstatements in financial statements.

Future Outlook

The company will require additional capital to continue to execute its strategy and anticipates raising this capital through various avenues, including sales of equity securities, debt transactions, licensing agreements, and collaborative arrangements.

Industry Context

The company operates in the competitive AI-driven drug discovery and development market, facing competition from established pharmaceutical companies, biotech firms, and other AI-focused startups. The success of Bullfrog AI depends on its ability to effectively leverage its bfLEAP platform, secure strategic partnerships, and advance its internal drug development programs.

Comparison to Industry Standards

• It is difficult to compare Bullfrog AI directly to industry standards due to its unique AI/ML platform and focus on rescuing failed drugs.
• However, similar companies in the AI-driven drug discovery space include Recursion Pharmaceuticals, Exscientia, and Schrödinger.
• These companies have varying revenue models, including partnerships with pharmaceutical companies and internal drug development programs.
• Bullfrog AI's financial performance and ability to secure funding will be key factors in its long-term success compared to these industry peers.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and potential dilution from future equity offerings.
• Employees face uncertainty regarding job security due to the company's financial challenges.
• Customers and partners may be concerned about the company's ability to fulfill its obligations.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will seek additional capital to continue to execute its strategy.
• The company will continue to implement improvements to its internal controls over financial reporting.
• The company will continue to develop and pursue new intellectual property.
• The company will continue to explore strategic partnerships and collaborations.

Key Dates

Keywords

AI/ML, bfLEAP, financial results, going concern, research and development, drug development, biopharmaceutical, clinical trials, intellectual property, internal controls